It is important to report the rest of that result honestly, though
Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
Consulting with a healthcare provider is essential, as they can provide guidance on whether a GLP-1 medication is appropriate for your health profile and goals and can also help to manage or avoid side effects through careful dose adjustment
The article's table compares four non-GLP-1 options by mechanism
This finding was very interesting because the cyclobutyl and cyclopropyl substitutions lead to a large difference in the efficacy of ADCs
Animal research has reported changes in circadian hormone measurements, ageing-related markers, tumour outcomes and lifespan in selected models
